Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPO. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIntercede Regulatory News (IGP)

Share Price Information for Intercede (IGP)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 107.00
Bid: 102.00
Ask: 112.00
Change: 0.00 (0.00%)
Spread: 10.00 (9.804%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 105.00
IGP Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Amendments to LTIP

21 Aug 2012 07:00

RNS Number : 3943K
Intercede Group PLC
21 August 2012
 

21 August 2012

Intercede Group plc

("Intercede" or "the Company"))

 

Changes to Long Term Incentive Plan (LTIP)

 

Intercede is pleased to announce that, following consultation with the Company's major shareholders, the Remuneration Committee has approved certain changes to the performance conditions attached to awards made under the Company's LTIP on 16 August 2011. The changes are a result of Richard Parris, the Company's Chairman & Chief Executive, communicating to the Remuneration Committee that he would not exercise options until the price per ordinary share exceeded 200p.

 

In considering this communication, the Remuneration Committee noted that Intercede's recently announced strategy of accelerated investment in technology development and the expansion of its US footprint and capabilities was not consistent with an EPS performance target under the LTIP. The Remuneration Committee consider, having taken appropriate advice, that the change in strategy represents an event under the terms of the LTIP that allows a change to performance targets to be made.

 

Consequently the Remuneration Committee has removed the three year EPS performance target from the LTIP awards made in August 2011 and replaced it with a share price target of 200p per ordinary share as well as extending the vesting period to seven years from the date of the original award. In order to exercise the option, an average share price of 200p per ordinary share must be achieved over 30 consecutive dealing days during the period between three years and seven years from the date of the original award.

 

In addition, participants have agreed to the insertion of a further performance condition. In the event of a recommended offer for the Company at any price below 125p per ordinary share, the option will only be exercisable over such number of shares that are equivalent in value to the difference between 56p (being the mid-market share price at the time of the original grant of 57p less the 1p exercise price) and the offer price. This also means that the option would not be exercisable at all at a recommended offer price of less than 57p. At any price above 125p, or in the event of an offer that is not recommended by the Board, the option vests in full.

 

All other terms and conditions of the LTIP remain unchanged.

 

Royston Hoggarth, the Chairman of the Remuneration Committee said: "Intercede is a global software company that needs to invest to increase its market penetration and long term valuation. The Remuneration Committee consider an overall share price target more appropriately aligns the interests of the beneficiaries of the LTIP and shareholders than a short or medium term EPS performance target. The willingness by Richard to communicate a share price target that is over three times higher than the price today, and the agreement by participants to the takeover condition, demonstrates their confidence and belief in the business."

 

 

 

 

 

 

ENQUIRIES

 

Intercede Group plc

Tel. +44 (0)1455 558111

Richard Parris, Chairman & Chief Executive

Andrew Walker, Finance Director

FinnCap

Tel. + 44 (0)20 7220 0500

Stuart Andrew/Rose Herbert, Corporate Finance

Joanna Weaving, Corporate Broking

Pelham Bell Pottinger

Tel. +44 (0)20 7861 3112

Archie Berens

 

About Intercede

Intercede® is a security software provider whose MyID® identity management platform enables global organisations and governments to create trusted digital identities for employees and citizens on secure devices such as smartcards, smartphones and tablets. MyID enables the protection of IP, assets, and digital content, delivering trusted digital identities as the cornerstone of cyber security strategies for government, defence, financial services and other industries.

The Company operates in global markets (including the US, Europe and Middle East) and works with large international partners including BT, Gemalto, HP, Microsoft, Oberthur, SafeNet, Symantec and Thales to deliver flexible digital identity solutions that are interoperable with other existing technologies and which are tailored to customer needs.

Corporations such as Boeing, Booz Allen Hamilton and Lockheed Martin,and governments including the USA, UK and Kuwait, trust Intercede's deep expertise to deliver effective solutions. The company's technology achievements reflect an investment of 300 plus man years of development, exemplary speed of deployment and adherence to international standards including FIPS 201, where MyID was the first electronic personalization product to obtain GSAapproval. This trust is reflected in Intercede's rate of repeat business with its customers, which typically runs at 70-80% of annual revenues.

Intercede has been developing ID management systems since 1992 and MyID is currently deployed by end customers located in 24 countries. The company is headquartered in the UK, listed on the London Stock Exchange AIM: IGP and ISO 9001 and TickIT certified.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCZMGZRDGLGZZM
Date   Source Headline
10th Aug 20227:00 amRNSNotice of AGM
30th Jun 20227:00 amRNSBoard Changes
8th Jun 20227:00 amRNSFinal Results
25th May 202210:15 amRNSInvestor Presentation
12th Apr 20227:00 amRNSAppointment of CFO
6th Apr 20227:00 amRNSDirector/PDMR Shareholding
5th Apr 20227:00 amRNSTrading Update & Contract Win
30th Mar 202210:01 amRNSReceipt of $3.4m Order
2nd Feb 20227:00 amRNSContract Win
8th Dec 20213:55 pmRNSDirector/PDMR Shareholding and Issue of Equity
23rd Nov 20217:00 amRNSHalf-year Report
19th Nov 20217:00 amRNSHolding(s) in Company-Amendment
17th Nov 20217:00 amRNSInvestor Presentation
16th Nov 20217:00 amRNSHolding(s) in Company
15th Nov 20213:45 pmRNSTotal Voting Rights
11th Nov 20214:12 pmRNSHolding(s) in Company
11th Oct 20217:00 amRNSTrading Update
15th Sep 20212:09 pmRNSResult of AGM
15th Sep 20217:00 amRNSMultiple Customers choose to Upgrade MyID
20th Jul 20217:00 amRNSIntercede achieves FIDO2 certification
5th Jul 20217:00 amRNSConnect Partner Programme & Q1 Contract Wins
15th Jun 20218:26 amRNSIssue of Equity
8th Jun 20217:00 amRNSFinal Results
2nd Jun 202110:09 amRNSInvestor Presentation
10th May 20217:00 amRNSShare Incentive Plan
7th Apr 20217:00 amRNSTrading Update & Appointment of Auditor
1st Apr 202110:30 amRNSReceipt of $3.4m Order
10th Mar 20217:00 amRNSShare Incentive Plan
23rd Feb 20217:00 amRNSAmendment to LTIP
22nd Feb 20214:10 pmRNSHolding(s) in Company
16th Feb 20217:00 amRNSCLN Conversion to Equity
12th Feb 20217:00 amRNSHolding(s) in Company
8th Feb 202112:40 pmRNSHolding(s) in Company
4th Feb 20217:00 amRNSCLN Call & Issue of Equity
11th Jan 20217:00 amRNSNew Contract Win
5th Jan 202111:00 amRNSCLN Conversion to Equity
4th Jan 202110:40 amRNSHolding(s) in Company
22nd Dec 20207:00 amRNSNew Contract Win
24th Nov 20207:00 amRNSHalf-year Report
17th Nov 20207:00 amRNSContract Win: Follow-on Purchase Order
12th Nov 20207:00 amRNSInvestor Presentation
8th Oct 20207:01 amRNSIntercede join the FIDO Alliance
8th Oct 20207:00 amRNSTrading Update
16th Sep 20203:40 pmRNSResult of AGM
20th Aug 20207:05 amRNSContract Win - Initial Progress Order
5th Aug 20202:01 pmRNSHolding(s) in Company
30th Jul 20207:00 amRNSContract Win
2nd Jun 20207:00 amRNSFinal Results
12th May 20207:00 amRNSShare Incentive Plan
20th Apr 202010:02 amRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.